文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

既往使用钙通道阻滞剂与脓毒症重症患者死亡率降低相关:一项前瞻性观察性研究

Prior Use of Calcium Channel Blockers Is Associated With Decreased Mortality in Critically Ill Patients With Sepsis: A Prospective Observational Study.
PubMed 文献 · Crit Care Med · 2017-01-01
一句话结论在荷兰两家三级医院ICU的脓毒症患者中,既往使用钙通道阻滞剂与30天生存改善相关(倾向匹配队列死亡率20.2% vs 32.9%,p=0.009)。

该前瞻性观察性研究纳入荷兰两家三级医院ICU连续收治的1,060例脓毒症患者,其中18.6%既往使用钙通道阻滞剂。因基线差异大,构建倾向评分匹配队列。匹配队列中既往使用钙通道阻滞剂者30天生存改善(死亡率20.2% vs 非使用者32.9%,p=0.009),多因素分析比值比0.48(95%CI 0.31-0.74,p=0.0007)。既往使用钙通道阻滞剂与反映细胞因子网络、血管内皮和凝血系统激活的血浆生物标志物水平变化无关,仅抗凝血酶水平下降较少。结论认为既往使用钙通道阻滞剂与脓毒症ICU患者死亡率降低相关。

要点

  • 倾向匹配队列中,既往使用钙通道阻滞剂者30天死亡率20.2%,非使用者32.9%(p=0.009)。
  • 多因素分析中既往使用钙通道阻滞剂与30天死亡风险降低相关:比值比0.48(95%CI 0.31-0.74,p=0.0007)。
  • 两组病情严重程度(前24小时)、感染部位和致病病原体相似。
  • 既往使用钙通道阻滞剂与细胞因子网络、血管内皮和凝血系统激活的血浆生物标志物水平变化无关。
  • 唯一例外是抗凝血酶水平在钙通道阻滞剂使用者中下降较少。

适用人群与场景

  • 荷兰两家三级医院ICU连续收治的脓毒症患者,共1,060例,其中18.6%既往使用钙通道阻滞剂。

研究设计与关键结果

  • 研究类型:前瞻性观察性研究;人群:荷兰两家三级医院ICU连续收治的1,060例脓毒症患者,18.6%既往使用钙通道阻滞剂。
  • 为校正基线差异构建倾向评分匹配队列;两组前24小时病情严重程度、感染部位和致病病原体相似。
  • 主要结果:倾向匹配队列中既往使用钙通道阻滞剂者30天死亡率20.2%,非使用者32.9%(p=0.009);多因素分析比值比0.48(95%CI 0.31-0.74,p=0.0007)。
  • 15种血浆生物标志物在入院后前4天测定:既往使用钙通道阻滞剂与反映细胞因子网络、血管内皮和凝血系统激活的标志物水平变化无关,仅抗凝血酶水平在钙通道阻滞剂使用者中下降较少。

证据类型、等级与局限

  • 证据类型:前瞻性观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该研究提示既往使用钙通道阻滞剂可能与脓毒症ICU患者30天生存改善相关,作者结论为既往使用钙通道阻滞剂与脓毒症ICU入院后死亡率降低相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Experimental studies suggest that calcium channel blockers can improve sepsis outcome. The aim of this study was to determine the association between prior use of calcium channel blockers and the outcome of patients admitted to the ICU with sepsis.

DESIGN: A prospective observational study.

SETTING: The ICUs of two tertiary care hospitals in the Netherlands.

PATIENTS: In total, 1,060 consecutive patients admitted with sepsis were analyzed, 18.6% of whom used calcium channel blockers.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Considering large baseline differences between calcium channel blocker users and nonusers, a propensity score matched cohort was constructed to account for differential likelihoods of receiving calcium channel blockers. Fifteen plasma biomarkers providing insight in key host responses implicated in sepsis pathogenesis were measured during the first 4 days after admission. Severity of illness over the first 24 hours, sites of infection and causative pathogens were similar in both groups. Prior use of calcium channel blockers was associated with improved 30-day survival in the propensity-matched cohort (20.2% vs 32.9% in non-calcium channel blockers users; p = 0.009) and in multivariate analysis (odds ratio, 0.48; 95% CI, 0.31-0.74; p = 0.0007). Prior calcium channel blocker use was not associated with changes in the plasma levels of host biomarkers indicative of activation of the cytokine network, the vascular endothelium and the coagulation system, with the exception of antithrombin levels, which were less decreased in calcium channel blocker users.

CONCLUSIONS: Prior calcium channel blocker use is associated with reduced mortality in patients following ICU admission with sepsis.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Wiewel MA, van Vught LA, Scicluna BP, et al. Prior Use of Calcium Channel Blockers Is Associated With Decreased Mortality in Critically Ill Patients With Sepsis: A Prospective Observational Study. Crit Care Med. 2017. PMID: 28079604. doi:10.1097/CCM.0000000000002236

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。